Optimizing IFN Beta - 1B Dose (Optims)

This study has been completed.

Sponsor:

Collaborator:

Dimensione Ricerca s.r.l.

Information provided by:

University of Turin, Italy

ClinicalTrials.gov Identifier:

NCT00473213

First received: May 11, 2007

Last updated: NA

Last verified: May 2007

History: No changes posted

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	February 2004
Estimated Primary Completion Date:	No date given

No publications provided by University of Turin, Italy

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group. Neutralizing antibodies in multiple sclerosis patients treated with 375 microg interferon-beta-1b. Expert Opin Biol Ther. 2009 Apr;9(4):387-97.

To Top